US Patent

US12128132 — Drug delivery formulations

Method of Use · Assigned to MedinCell SA · Expires 2040-09-11 · 14y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating psychiatric diseases and disorders using an injectable risperidone formulation with a concentration of 250-400 mg/mL in a 1 mL or less injection volume.

USPTO Abstract

The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-601 — Risperdal
U-543 — Risperdal
U-543 — Risperdal
U-543 — Risperdal
U-543 — Risperdal
U-601 — Risperdal
U-601 — Risperdal

Patent Metadata

Patent number
US12128132
Jurisdiction
US
Classification
Method of Use
Expires
2040-09-11
Drug substance claim
No
Drug product claim
Yes
Assignee
MedinCell SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.